Reyon Pharmaceutical

이연제약 · 102460

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$134.6M (₩185.7B)

Overview

Reyon Pharmaceutical makes prescription medicines, including antibiotics, cardiovascular, digestive, and respiratory drugs, as well as a contrast agent used in CT scans and active pharmaceutical ingredients supplied to other drug makers.

Listed on KOSPI, Korea's main stock exchange, it serves hospitals, clinics, and pharmaceutical manufacturers. Its revenue is spread across three streams, prescription drugs, the CT contrast agent Optiray distributed under an exclusive domestic supply agreement with ISK (Imaging Solution Korea), and raw pharmaceutical ingredients such as tacrolimus and teicoplanin.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$105.7M

▼ −1.6% YoY

Operating profit · FY2025

−US$21.9M

Turned to loss

Net income · FY2025

−US$21.5M

Turned to loss

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$109.5M(₩151.1B)	US$107.5M(₩148.3B)	US$105.7M(₩145.9B)
Operating profit	US$2.9M(₩4B)	US$57.4K(₩79.3M)	−US$21.9M(−₩30.3B)
Net income	US$2.6M(₩3.6B)	US$3M(₩4.2B)	−US$21.5M(−₩29.6B)

Revenue

FY2023US$109.5M
FY2024US$107.5M
FY2025US$105.7M

Operating profit

FY2023US$2.9M
FY2024US$57.4K
FY2025−US$21.9M

Net income

FY2023US$2.6M
FY2024US$3M
FY2025−US$21.5M

Key ratios (FY2025)

ROE

-13.4%

Debt/Eq

111.2%

Op. margin

-20.7%

Net margin

-20.3%

Rev. YoY

▼ −1.6%

Why it matters

Reyon operates a dedicated biopharmaceutical manufacturing facility in Cheongju that has obtained Korean GMP certification for both chemical and biological medicines, and it pursues a contract manufacturing (CMO) business model alongside its own drug pipeline.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?